Quark Pharmaceutical announces initiation of patient recruitment for global pivotal study of QPI-1007 in NAION
Quark Pharmaceuticals, Inc., a late clinical-stage pharmaceutical company, who is a leader in the discovery and development of novel RNA interference (RNAi)-based therapeutics, has announced that...